Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites
详细信息 查看全文
- 作者：William R Swindell ; Mrinal K Sarkar ; Philip E Stuart…
- 关键词：AP ; 1 ; Decoy oligonucleotide ; IRF ; Motif ; NF ; kappaB ; ODN ; Position weight matrix ; STAT
- 刊名：Clinical and Translational Medicine
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：4
- 期：1
- 全文大小：2,575 KB
- 参考文献：1. Lowes, MA, Suarez-Farinas, M, Krueger, JG (2014) Immunology of psoriasis. Annu Rev Immunol 32: pp. 227-55
2. Boehncke, WH, Boehncke, S (2014) More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly 144: pp. w13968
3. Feldman, SR, Burudpakdee, C, Gala, S, Nanavaty, M, Mallya, UG (2014) The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 14: pp. 1-21
4. Lernia, V, Ricci, C, Lallas, A, Ficarelli, E (2014) Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatol Treatment 25: pp. 73-4
5. Kivelevitch, D, Mansouri, B, Menter, A (2014) Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biol Targets Therapy 8: pp. 169-82
6. Kragballe, K, Kerkhof, PC, Gordon, KB (2014) Unmet needs in the treatment of psoriasis. European J Dermatol 24: pp. 523-532
7. Latchman, DS (1996) Transcription-factor mutations and disease. N Engl J Med 334: pp. 28-33
8. Mason, A, Mason, J, Cork, M, Hancock, H, Dooley, G (2013) Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. J Am Acad Dermatol 69: pp. 799-807
9. Kivelevitch, DN, Hebeler, KR, Patel, M, Menter, A (2013) Emerging topical treatments for psoriasis. Expert Opinion Emerging Drugs 18: pp. 523-32
10. Goldminz, AM, Au, SC, Kim, N, Gottlieb, AB, Lizzul, PF (2013) NF-kappaB: an essential transcription factor in psoriasis. J Dermatol Sci 69: pp. 89-94
11. Lu, X, Du, J, Liang, J, Zhu, X, Yang, Y, Xu, J (2013) Transcriptional regulatory network for psoriasis. J Dermatol 40: pp. 48-53
12. Tsoi, LC, Spain, SL, Knight, J, Ellinghaus, E, Stuart, PE, Capon, F (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44: pp. 1341-8
13. Mann, MJ, Whittemore, AD, Donaldson, MC, Belkin, M, Conte, MS, Polak, JF (1999) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354: pp. 1493-8
14. Mann, MJ (2005) Transcription factor decoys: a new model for disease intervention. Ann N Y Acad Sci 1058: pp. 128-39
15. Yuan, HF, Huang, H, Li, XY, Guo, W, Xing, W, Sun, ZY (2013) A dual AP-1 and SMAD decoy ODN suppresses tissue fibrosis and scarring in mice. J Investigative Dermatol 133: pp. 1080-7
16. Wagner, AH, Wittjen, I, Stojanovic, T, Middel, P, Meingassner, JG, Hecker, M (2008) Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity. J Allergy clin Immunol 121: pp. 158-65
17. Sano, S, Chan, KS, Carbajal, S, Clifford, J, Peavey, M, Kiguchi, K (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: pp. 43-9
18. Yao, Y, Richman, L, Morehouse, C, de los Reyes, M, Higgs, BW, Boutrin, A (2008) Type I interferon: potential therapeutic target for psoriasis?. PLoS One 3: pp. e2737
19. Johnston, A, Guzman, AM, Swindell, WR, Wang, F, Kang, S, Gudjonsson, JE (2014) Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. British J Dermatol 171: pp. 97-107
20. Nair, RP, Duffin, KC, Helms, C, Ding, J, Stuart, PE, Goldgar, D (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: pp. 199-204
21. Suarez-Farinas, M, Li, K, Fuentes-Duculan, J, Hayden, K, Brodmerkel, C, Krueger, JG (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Investigative Dermatol 132: pp. 2552-64
22. Swindell, WR, Xing, X, Stuart, PE, Chen, CS, Aphale, A, Nair, RP (2012) Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One 7: pp. e34594
23. Bigler, J, Rand, HA, Kerkof, K, Timour, M, Russell, CB (2013) Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLoS One 8: pp. e52242
24. Sofen, H, Smith, S, Matheson, RT, Leonardi, CL, Calderon, C, Brodmerkel, C (2014) Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 133: pp. 1032-40
25. Swindell, WR, Johnston, A, Xing, X, Little, A, Robichaud, P, Voorhees, JJ (2013) Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. Scientific Reports 3: pp. 1215
26. Edwards, SL, Beesley, J, French, JD, Dunning, AM (2013) Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet 93: pp. 779-97
27. Elder, JT, Bruce, AT, Gudjonsson, JE, Johnston, A, Stuart, PE, Tejasvi, T (2010) Molecular dissection of psoriasis: integrating - 刊物主题：Medicine/Public Health, general;
- 出版者：Springer Berlin Heidelberg
- ISSN：2001-1326
文摘
Background Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive biologic agents. These medications, however, are not equally effective in all patients and are poorly suited for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor (TF) activity is a promising strategy. Methods Meta-analysis was used to identify differentially expressed genes (DEGs) in the lesional skin from psoriasis patients (n--37). We compiled a dictionary of 2935 binding sites representing empirically-determined binding affinities of TFs and unconventional DNA-binding proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements-(PREs) overrepresented in sequences upstream of psoriasis DEGs. Results PREs are recognized by IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical (high-mobility group) DNA-binding domains. We identified a limited set of DEGs that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1, SOX5) and uDBPs (AVEN, RBM8A, GPAM, WISP2). PREs were prominent within enhancer regions near cytokine-encoding DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy oligonucleotides (cdODNs). To illustrate this idea, we designed a cdODN to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are disproportionately disrupted by psoriasis risk alleles. Conclusions We identified new TF/uDBP candidates and developed an approach that (i) connects transcriptome informatics to cdODN drug development and (ii) enhances our ability to interpret GWAS findings. Disruption of PRE motifs by psoriasis risk alleles may contribute to disease susceptibility.